Analyst Robert Wasserman of Benchmark Co. maintained a Buy rating on Ligand Pharma (LGND – Research Report), retaining the price target of $135.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Robert Wasserman has given his Buy rating due to a combination of factors including Ligand Pharma’s strong financial performance in the first quarter of 2025, where the company reported a significant year-over-year revenue increase of 46% and adjusted earnings per share that exceeded expectations. This growth was largely driven by increased sales of their Captisol excipient and higher royalty revenues from several licensed products. Additionally, the successful spin-off of Pelthos Therapeutics and the acquisition of a Phase 3 asset through a deal with Castle Creek Biosciences further bolster Ligand’s growth prospects.
Looking forward, Wasserman anticipates continued revenue growth fueled by new product royalties and steady earnings per share for the upcoming quarters. The company’s reaffirmed financial guidance for the full year 2025, along with several potential catalysts such as new product launches and clinical progress from partners, supports the Buy rating. The price target of $135 reflects a valuation that aligns with other high-growth bioprocessing stocks, suggesting a substantial potential for share price appreciation.
According to TipRanks, Wasserman is an analyst with an average return of -2.6% and a 37.41% success rate. Wasserman covers the Healthcare sector, focusing on stocks such as Integer Holdings, Halozyme, and Ligand Pharma.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $157.00 price target.